Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)‘s stock had its “hold” rating reissued by investment analysts at Janney Montgomery Scott in a research report issued on Wednesday. They currently have a $47.00 price target on the specialty pharmaceutical company’s stock. Janney Montgomery Scott’s price objective points to a potential upside of 27.89% from the company’s previous close.

SUPN has been the subject of a number of other research reports. BidaskClub cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 2nd. Jefferies Group LLC reiterated a “buy” rating and issued a $51.00 target price on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. Cowen and Company reiterated a “positive” rating and issued a $50.00 target price (up previously from $40.00) on shares of Supernus Pharmaceuticals in a research note on Thursday, August 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a $47.00 target price (up previously from $36.00) on shares of Supernus Pharmaceuticals in a research note on Tuesday, July 18th. Finally, Piper Jaffray Companies reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, August 4th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $48.29.

Supernus Pharmaceuticals (SUPN) traded down 3.42% during mid-day trading on Wednesday, reaching $36.75. The company had a trading volume of 2,357,784 shares. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of 18.54 and a beta of 1.30. The company’s 50 day moving average is $44.56 and its 200 day moving average is $37.95. Supernus Pharmaceuticals has a 52-week low of $17.25 and a 52-week high of $50.05.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.08. Supernus Pharmaceuticals had a net margin of 41.10% and a return on equity of 30.73%. The company had revenue of $75.83 million during the quarter, compared to analysts’ expectations of $68.54 million. Equities analysts predict that Supernus Pharmaceuticals will post $1.04 earnings per share for the current year.

WARNING: “Janney Montgomery Scott Reaffirms Hold Rating for Supernus Pharmaceuticals, Inc. (SUPN)” was first published by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/09/20/janney-montgomery-scott-reaffirms-hold-rating-for-supernus-pharmaceuticals-inc-supn.html.

In related news, CFO Gregory S. Patrick sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $47.60, for a total value of $2,380,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Padmanabh P. Bhatt sold 3,735 shares of the business’s stock in a transaction that occurred on Wednesday, July 12th. The stock was sold at an average price of $44.90, for a total transaction of $167,701.50. Following the completion of the transaction, the vice president now owns 21,209 shares of the company’s stock, valued at approximately $952,284.10. The disclosure for this sale can be found here. Insiders sold a total of 160,000 shares of company stock valued at $7,505,574 in the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently bought and sold shares of SUPN. BlackRock Inc. raised its position in Supernus Pharmaceuticals by 156,173.3% in the 1st quarter. BlackRock Inc. now owns 6,696,310 shares of the specialty pharmaceutical company’s stock worth $209,595,000 after purchasing an additional 6,692,025 shares during the last quarter. Vanguard Group Inc. raised its position in Supernus Pharmaceuticals by 39.1% in the 2nd quarter. Vanguard Group Inc. now owns 3,500,535 shares of the specialty pharmaceutical company’s stock worth $150,873,000 after purchasing an additional 984,200 shares during the last quarter. Emerald Advisers Inc. PA bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $21,474,000. Emerald Mutual Fund Advisers Trust bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $17,553,000. Finally, Hodges Capital Management Inc. bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $17,220,000. Hedge funds and other institutional investors own 95.38% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.